NAVIGATING THE COMPLEXITIES OF AMYOTROPHIC LATERAL SCLEROSIS: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS

The progressive neurodegenerative disease known as amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons, which eventually results in atrophy, weakening, and paralysis of the muscles. A thorough summary of the state of knowledge regarding ALS is given in this review, which includes information on the disease's pathophysiology, epidemiology, etiology, clinical manifestations, diagnostic standards, and treatment options. Recent scientific developments—such as the identification of novel therapeutic approaches, biomarker development, and genetic discoveries—are highlighted. The study seeks to draw attention to the difficulties and potential paths forward for ALS clinical care and research. Degeneration of motor neurons is the cause of the debilitating disease known as amyotrophic lateral sclerosis (ALS). For a variety of reasons, the development of disease-modifying medicines has proven difficult, as it does with all major neurodegenerative conditions. However, ALS is among the select few neurodegenerative illnesses for which treatment with disease-modifying agents is authorized. Over the past ten to fifteen years, significant advancements and discoveries have been achieved in the fields of genetics, pathology, imaging, biomarkers, ALS preclinical models, and clinical readouts. In the meantime, new treatment approaches are being used in high-unmet medical need areas, such as neurodegenerative diseases. Our understanding base has expanded as a result of these advancements, making it possible to identify targeted candidate therapeutics for ALS with a variety of modes of action. In this Review, we go over how this new understanding combined with fresh methods can facilitate efficient translation. KEYWORDS: amyotrophic lateral sclerosis; epidemiology; pathophysiology; diagnosis; Pharmacological therapies, Incidence and prevalence of ALS, clinical trials, supportive therapy.